Neurocognitive aging and cognitive disorders

Tabeeva G.R.

doi:https://doi.org/10.17116/jnevro2019119061160

Close metadata

Recommended articles:

Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Curcumin-induced increased retinal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25

Differential diagnosis of Alzheimer’s disease and vascular cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35

Change of subjective cognitive decline in first-degree relatives of patients with Alzheimer’s disease: results of a 15-year prospective study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):36-42

A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53

Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60

Treatment features of patients with vascular cognitive impairments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):69-76

Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20

The fundamental foundations of periodontal aging. Part 1. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2):63-69

Abstract:

Aging is the leading risk factor of the most common cognitive disorders, primarily Alzheimer’s disease and vascular dementia. These diseases have a progressive course and pathological underlying processes develop long before the onset of clinical signs of cognitive impairment. In the context of current trends in population aging and the steady increase in the number of patients with dementia, the search for factors contributing to the acceleration of neurocognitive aging processes, as well as factors with a modifying effect on these processes, is a key element in the effective management of elderly patients.

Keywords:

aging

dementia

mild cognitive impairment

subjective cognitive impairment

Alzheimer’s disease

vascular dementia

vascular cognitive impairment

Authors:

Tabeeva G.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Close metadata

References:

Harada CN, Love MCN, Triebel K. Normal Cognitive Aging. Clin Geriatr Med. 2013;29(4):737-752. https://doi.org/10.1016/j.cger.2013.07.002
Salthouse T. Consequences of age-related cognitive declines. Annual Review of Psychology. 2012;63:201-226. https://doi.org/10.1146/annurev-psych-120710-100328
Darowski ES, Helder E, Zacks RT, Hasher L, Hambrick DZ. Age-related differences in cognition: the role of distraction control. Neuropsychology. 2008;22:638-644. https://doi.org/10.1037/0894-4105.22.5.638
Davis HP, Klebe KJ, Guinther PM, Schroder KB, Cornwell RE, James LE. Subjective organization, verbal learning, and forgetting across the life span: from 5 to 89. Experimental aging Research. 2013;39:1-26. https://doi.org/10.1080/0361073X.2013.741956
Ronnlund M, Nyberg L, Backman L, Nilsson LG. Stability, growth, and decline in adult life span development of declarative memory: cross-sectional and longitudinal data from a population-based study. Psychology and Aging. 2005;20:3-18. https://doi.org/10.1037/0882-7974.20.1.3
Hayden KM, Welsh-Bohmer KA. Epidemiology of cognitive aging and Alzheimer’s disease: contributions of the cache county utah study of memory, health and aging. Current Topics in Behavioral Neurosciences. 2012;10:3-31. PubMed: 21809193. https://doi.org/10.1007/7854_2011_152
Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology. 2004;62:433-438.
Rodrigue KM, Kennedy KM, Park DC. Beta-amyloid deposition and the aging brain. Neuropsychology Review. 2009;19:436-450.
Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain: a Journal of Neurology. 2008;131:665-680. https://doi.org/10.1093/brain/awm336
Terry RD, Katzman R. Life span and synapses: will there be a primary senile dementia? Neurobiology of Aging. 2001;22:347-348. discussion 53-54.
Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR. Changes in the structural complexity of the aged brain. Aging Cell. 2007;6:275-284. https://doi.org/10.1111/j.1474-9726.2007.00289.x
Salat DH, Kaye JA, Janowsky JS. Prefrontal gray and white matter volumes in healthy aging and Alzheimer disease. Archives of Neurology. 1999;56:338-344.
Rogalski E, Stebbins GT, Barnes CA, Murphy CM, Stoub TR, George S, Ferrari C, Shah RC, deToledo-Morrell L, et al. Age-related changes in parahippocampal white matter integrity: a diffusion tensor imaging study. Neuropsychologia. 2012;50:1759-1765. https://doi.org/10.1016/j.neuropsychologia.2012.03.033
O’Sullivan M, Summers PE, Jones DK, Jarosz JM, Williams SC, Markus HS. Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study. Neurology. 2001;57:2307-2310.
Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819-828. https://doi.org/10.1016/s1474-4422(11)70072-2
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204. https://doi.org/10.1212/01.wnl.0000271090.28148.24
Vermeer SE, Prins ND, Heijer TD, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222. https://doi.org/10.1056/NEJMoa022066
Pendlebury ST, Rothwell PM. Prevalence, incidence, andfactors associated with pre-stroke and post-stroke dementia: asystematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018. https://doi.org/10.1016/S1474-4422(09)70236-4
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain. 2013;136:2697-2706. https://doi.org/10.1093/brain/awt188
Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatric Disease and Treatment. 2017;13:491-498. https://doi.org/10.2147/NDT.S123428
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment— beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246. https://doi.org/10.1111/j.1365-2796.2004.01380.x
Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimer’s Dement. 2012;8(1):14-21. https://doi.org/10.1016/j.jalz.2011.01.002
Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214-228. https://doi.org/10.1111/joim.12190
Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320-332. https://doi.org/10.1159/000354370
Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H. German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414-422. https://doi.org/10.1001/archgenpsychiatry.2010.30
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, GlodzikL, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M. Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2014;10(6):844-852. https://doi.org/10.1016/j.jalz.2014.01.001
Caselli RJ, Chen K, Locke DE, Lee W, Roontiva A, Bandy D, Fleisher AS, Reiman EM. Subjective cognitive decline: self and informant comparisons. Alzheimer’s Dement. 2014;10(1):93-98. https://doi.org/10.1016/j.jalz.2013.01.003
Fernandez-Blazquez MA, Avila-Villanueva M, Maestu F, Medina M. Specific features of subjective cognitive decline predict faster conversion to mild cognitive impairment. J Alzheimer’s Dis. 2016;52(1):271-281. https://doi.org/10.3233/JAD-150956
Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C. Alzheimer’s Neuroimaging Initiative. Integration and relative value of bio-markers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin. 2014;4:164-173. https://doi.org/10.1016/j.nicl.2013.11.010
Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 2013;80(7):648-654. https://doi.org/10.1212/WNL.0b013e318281ccd3
Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(4):323-334. https://doi.org/10.1176/appi.ajp.2014.14070878
Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB. Impact of hypertension on cognitive function. A scientific statement from the American Heart Association. Hypertension. 2016;68(6):67-94. https://doi.org/10.1161/HYP.0000000000000053
Institute of Medicine Brief Report. Cognitive aging: progress in understanding and opportunities for action, April 2015. Accessed 1 May 2017. http://www.iom.edu/cognitiveaging
Lautenschlager NT, Cox KL, Flicker L, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027-1037. https://doi.org/10.1001/jama.300.9.1027
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397.
Eshkoor SA, Hamid TA, Mun CY, Ng CK. Mild cognitive impairment and its management in older people. Clin Interv Aging. 2015;10:687-693. https://doi.org/10.2147/CIA.S73922
Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017;31(9):759-776. https://doi.org/10.1007/s40263-017-0459-3
Frankiewicz T, Pilc A, Parsons CG. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology. 2000;39:631-642.
Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
Wilcock G, Mobius HJ, Stoffler A, MMM 500 Group. A double- blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305.
Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2016;33(4):1-6. (In Russ.) https://doi.org/10.7868/S1027813316040166
Fedin AI, Belskaya GN, Kurushina OV, Kovalchuk VV, Starich EV, Chichanovskaya LV, Baranova OA. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(9):35-42. (In Russ.) https://doi.org/10.17116/jnevro201811809135
Fedin AI. The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;1:30-36. (In Russ.) https://doi.org/10.17116/jnevro20181181130-36